ArticleAnnals of vascular diseases2026
Characteristics of Cancer-Associated Thrombosis Based on Changes in Clinically Measurable Coagulation Factors and Coagulation/Fibrinolysis Markers in Patients with Cancer: A Multicenter Cross-Sectional Study.
Article in Annals of vascular diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This exploratory, cross-sectional study aimed to examine the association between coagulation factor activity and coagulation/fibrinolysis markers and the presence of cancer-associated thrombosis (CAT). Methods: Patients diagnosed with cancer complicated by thrombosis and those without thrombosis between November 1, 2020, and December 31, 2022 were included. The clinical characteristics and values of each coagulation factor and coagulation/fibrinolysis marker in the CAT and non-CAT groups were compared. Results: Of the 117 patients analyzed, 22 (18.8%) had CAT and 95 (81.2%) did not have CAT. Fibrinogen/fibrin degradation product (FDP), D-dimer, alpha2-plasmin inhibitor-plasmin complex (PIC), fibrin monomer complex (FMC), thrombin-antithrombin complex (TAT), and soluble fibrin (SF) levels were significantly higher in the CAT group than that in the non-CAT group. Receiver operating characteristic curve analysis was performed, and the proportions of patients with CAT were 7.9% when the number of factors with a value higher than the cutoff was 0 among the 6 factors of FDP, D-dimer, PIC, FMC, TAT, and SF levels; 17.1% for factors 1-3 and 31.6% for factors 4-6. Conclusions: When hypercoagulability and hyperfibrinolysis coexist in patients with cancer, CAT is likely to be present, and it is necessary to confirm the presence of CAT at an early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.